Dr. McMasters is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
NWH Cancer Center
2014 Washington Street
Newton, MA 02462Phone+1 617-219-1230Fax+1 617-831-7331
Education & Training
Westchester Medical CenterFellowship, Hematology and Medical Oncology, 2006 - 2009
Zucker School of Medicine at Hofstra/Northwell at Lenox Hill HospitalResidency, Internal Medicine, 2003 - 2006
Medical University of SilesiaClass of 1995
Certifications & Licensure
MA State Medical License 2009 - 2026
NY State Medical License 2009 - 2011
NJ State Medical License 2009 - 2009- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- Phase I Trial of Cabozantinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2013 Nov 01
- Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults Start of enrollment: 2014 Dec 01
- Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia Start of enrollment: 2016 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- 26 citationsCabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation.Amir T. Fathi, Traci M. Blonquist, Daniela Hernandez, Philip C. Amrein, Karen K. Ballen
Cancer. 2018-01-15 - 97 citationsPhase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms.David P. Steensma, Martin Wermke, Virginia M. Klimek, Peter L. Greenberg, Patricia Font
Leukemia. 2021-06-25 - 124 citationsMUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemiaAthalia Rachel Pyzer, Dina Stroopinsky, Hasan Rajabi, Abigail Washington, Ashujit Tagde
Blood. 2017-03-30
Abstracts/Posters
- A Phase I Study of Asciminib (ABL001) in Combination with Dasatinib and Prednisone for Untreated BCR-ABL1-Positive ALL in Older AdultsMalgorzata McMasters, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic...Malgorzata McMasters, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
